Table 1 Patient characteristics and clinical outcomes to axitinib
From: Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
Characteristic | N (%) |
|---|---|
Gender | |
Male | 18 (72 %) |
Female | 7 (28 %) |
Age at Start of Axitinib (years)a | |
Median (range) | 59 (44-78) |
Histology | |
Clear cell | 24 (96 %) |
Unclassified | 1 (4 %) |
Prior Nephrectomy | |
No | 2 (8 %) |
Yes | 23 (92 %) |
Prior Systemic Treatment | |
No | 7 (28 %) |
Yes | 18 (72 %) |
IFN and/or IL-2 | 11 (44 %) |
Sorafenib | 9 (36 %) |
Sunitinib | 6 (24 %) |
Temsirolimus | 1 (4 %) |
Bevacizumab | 1 (3 %) |
Otherb | 4 (16 %) |
Interval from Dx of Mets to Axitiniba | |
Median in months (range) | 20.1 (0.2–49.9) |
ECOG PS | |
0 | 7 (28 %) |
1 | 18 (72 %) |
Heng Risk Groupc | |
Favorable | 7 (30 %) |
Intermediate | 15 (65 %) |
Unfavorable | 1 (4 %) |
Sites of Metastatic Disease | |
Lung | 20 (80 %) |
Lymph nodes | 13 (52 %) |
Bone | 6 (24 %) |
Liver | 5 (20 %) |
Adrenal | 5 (20 %) |
Pancreas | 4 (16 %) |
Brain | 2 (8 %) |
Otherd | 12 (48 %) |
Best Response to axitinib | |
CR | 1 (4 %) |
PR | 13 (52 %) |
SD | 10 (40 %) |
PD | 1 (4 %) |
Reason Axitinib Stopped | |
PD | 21 (84 %) |
Toxicity | 4 (16 %) |
Duration of Treatment | |
Median in months (range) | 11.2 (1.1–90.0) |